The problem
For thirty years, biotech works in the lab. The molecules are there, the reactions are clean and the results are valid. Then comes the only test that matters: industrial-scale production.
And almost everything breaks.
Biotech only scales when the process is simple. Everything else is too slow, too unpredictable and too far from the conditions in a real plant.
For thirty years, the industry has been waiting for a biotech process that finally can be implemented at industrial scale.
Our solution
Our modular biocatalysis platform is designed for industrial conditions from day one.
We can deliver a go/no-go in days. Industrial POC in months, not years. Including the molecules petrochemistry has long claimed as its own.
Forgen's platform works with life, not against it, and at the scale industry needs.
Our technology
Forgen decouples biocatalysis from cell growth and runs it in a distinct cellular compartment, so reactions stay stable at scale.
Hosting reactions in a dedicated compartment, separate from central metabolism, avoids the toxicity and genetic instability that block conventional strains.
Enzymes assemble into modular cascades, screened in silico and validated experimentally from substrate to target molecule.
The result: titers, yields, and economics that hold from lab to industrial scale.
Most natural molecules (the aromas, the active ingredients, the specialty compounds the chemical industry needs) were until now beyond what biotech could deliver at scale.
Forgen makes them accessible and cost-competitive. Without trade-offs on quality or naturality.
Forgen's platform is built for adoption, not disruption.
Routes are designed to integrate into industrial production with minimal infrastructure change so our partners can scale without rebuilding their facilities.
Applications
From flavors to pharma, Forgen unlocks the molecules
a
multi-billion-euro market has been waiting for.
Benchmark
For decades, industrials had to choose between fossil reliability
and uncertain promises. Now there's a third option.
Chemical catalysis
Single-strain, whole-cell, cytoplasmic metabolism
Multi-strain, modular biocatalyst consortia
High temperature, high pressure, heavy metals
Mild but unstable (metabolic drift)
Mild, stable, reproducible
10+ years
5-10+ years
Go / no-go in days
Industrial route in months
Wide but fossil only
Narrow and case-by-case
Broad, including high-value molecules
Tied to oil price volatility
Low: scale-ups often fail
Validated before commitment
Synthetic and under pressure
Bio-based, narrow scope
Natural, even at industrial scale
About us
Our company has spent years engineering a modular biocatalysis platform built for industrial reality.
With direct access to one of Europe's most advanced biocatalysis facilities, we have grown a portfolio of proven molecules, and we keep adding to it.
Our mission is simple: to unlock nature's full industrial potential.
People
A founding team built to industrialize biotech, supported by leading voices in industrial biocatalysis.
CSO - Enzyme engineering and biocatalysis
CEO - Industrial biotech and company building
CTO - Bioprocess scale-up and industrialization
40+ years in industrial biotech, co-founded multiple biotech companies
25+ years in biochemistry, expertise in biochemistry and protein folding
25+ years in enzymology. Enzyme engineering, multiple awards
30+ years in pharma-chemical industries. Specialist in industrialization process.
Former VP research at BASF
30+ years in biocatalysis. Expert in biocatalysis and bio-oxidation process
Backed by :
Contact
Interested in partnering or learning more about our capabilities? Want to request a free feasibility study?
